Arthur Caplan of New York University discusses the issue of allowing expanded access for investigational drugs, often called compassionate use. He presents the case of Josh Hardy, a child with a rare form of kidney cancer whose family pleaded for compassionate use of a drug under development by the pharmaceutical company Chimerix. Josh eventually received the drug, and it helped him recover partially, however such success cases are rare. Today, Right-to-Try laws are gaining in popularity, but according to Caplan they are ineffectual and misguided. Caplan would proposes a system that allows for compassionate use and removes the disincentives for companies to participate, yet is budgetarily limited to a small portion of healthcare spending.
YOU MIGHT ALSO LIKE
"We have used HealthPolicy.tv to generate ideas about who to invite to campus to speak. There are a lot of great lecturers represented here."
— Jessica F., Chicago, IL